Doz

Posaconazole

پوساکونازول

⚠ Unverified

🦠 Antiinfectives For Systemic UseAzole antifungal

🤰 Pregnancy:Dangerous / avoid🤱 Breastfeeding:Use with caution👶 Children:Use with caution👴 Older adults:No specific problem stated 🇮🇷 Registered in Iran⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA022003ATC J02AC04

Market / country: 🇺🇸 USA

Noxafil (US)

🧮 Dose calculator

Invasive fungal infection (aspergillosis, candidaemia, cryptococcosis) — hospital · Regimen source: FDA Noxafil · 2.2, Table 1

Enter age and weight.

🛡️ Safety & information

Contraindications

  • ⛔ Hypersensitivity to posaconazole or other azoles; sirolimus; pimozide and quinidine (QT); CYP3A4-metabolised statins (simvastatin, lovastatin, atorvastatin); ergot alkaloids; venetoclax at initiation for CLL. FDA Noxafil · 4

Warnings

  • • QT prolongation; hepatotoxicity; many CYP3A4 drug interactions. FDA Noxafil · 5

Formulations

  • 100 mg delayed-release tablet (NOT interchangeable with suspension) — tablet 🇺🇸 USA FDA Noxafil · 3
  • 40 mg/mL oral suspension (NOT interchangeable with tablets) — suspension 🇺🇸 USA FDA Noxafil · 3

👥 Special populations

  • 🤰 PregnancyDangerous / avoid

    Label: can cause fetal harm. Dangerous in pregnancy. FDA Noxafil · 8.1

    “Risk Summary Based on findings from animal data, Noxafil may cause fetal harm when administered to pregnant women.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Noxafil · 8.2

    “Risk Summary There are no data on the presence of posaconazole in human milk, the effects on the breastfed infant, or the effects on milk production.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Noxafil · 8.4

    “Treatment of Invasive Aspergillosis The safety and effectiveness of Noxafil (injection and delayed-release tablets) have been established for the treatment of invasive aspergillosis in pediatric patients 2 years of age and older .”
  • 👴 Older adultsNo specific problem stated

    Label: no specific difference or dose adjustment stated for older adults. FDA Noxafil · 8.5

    “No overall differences in the safety or effectiveness of Noxafil injection, Noxafil delayed-release tablets, and Noxafil oral suspension have been observed between geriatric patients and younger adult patients in the clinical trials; therefore, the recommended dosage in geriatric patients is the same as that for …”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav